Anyone in the United States who could become infected after household contact with a COVID-positive person now has a new option. XOCOVA, a five-day pill from Japanese company Shionogi, reduces the risk of COVID disease after exposure by 67 percent. The US Food and Drug Administration (FDA) approved the drug on June 1, 2026, as the world's first oral medication for preventing COVID-19 after contact with an infected person. For immunocompromised individuals, older adults, and nursing home residents, this fundamentally changes the situation.
What is XOCOVA and how does it work?
The active ingredient ensitrelvir blocks an enzyme that SARS-CoV-2 needs to replicate: the 3CL protease. Without this enzyme, viral particles cannot fully assemble within the cell. The logic differs from vaccination. Rather than priming the immune system in advance, the drug directly intervenes in the early replication phase, before the virus establishes itself in the body.
Application is tied to a specific situation: people living in the same household as an infected person, who test negative on their own test and show no symptoms. According to FDA approval documents, the regimen consists of three tablets on the first day and one tablet each on days two through five. Ensitrelvir was already approved in Japan since 2022 as a COVID-19 treatment. However, the US approval for post-exposure prophylaxis represents the world's first use of this active ingredient in this indication and for COVID-19 generally.
What the SCORPIO-PEP trial showed
The FDA approval rests on the SCORPIO-PEP trial, a global, randomized, placebo-controlled Phase-3 study with 2,387 participants aged 12 and older. All participants lived in the same household with an infected person, had negative test results at study enrollment, and had no symptoms. The outcome after ten days, according to Shionogi's press statement: in the ensitrelvir group, 2.9 percent developed symptomatic COVID-19, compared to 9.0 percent in the placebo group. This corresponds to a risk reduction of 67 percent.
According to the FDA, the study is the only Phase-3 trial of an oral antiviral to achieve its primary endpoint in preventing COVID-19 after exposure. The data were published on May 14, 2026, in the New England Journal of Medicine. Tolerability was good. 15.1 percent in the ensitrelvir group and 15.5 percent in the placebo group reported side effects, nearly identical rates.
For whom the approval is particularly relevant
Vaccines effectively protect most of the population against severe COVID. For a specific group, this mechanism works less well: people with immunosuppression often form insufficient antibodies after vaccination. This applies to those after organ transplantation, during chemotherapy, or with HIV infection. For them, exposure risk remains elevated despite vaccination.
Ensitrelvir takes a different route. The drug works regardless of immune status because it does not rely on an antibody response but directly intervenes in viral replication. It is explicitly designed for people in whom vaccines alone provide insufficient protection. According to FDA approval, XOCOVA is approved for people aged 12 and older, regardless of risk factors.
By comparison: PEP has proven effective with other viruses
The idea of medically preventing a virus from breaking out shortly after exposure is not new. With HIV, post-exposure prophylaxis (PEP) has been standard since the 1990s. The 28-day antiretroviral course must begin within 72 hours of possible exposure and reduces HIV infection risk by more than 80 percent, according to the US National Institutes of Health. For healthcare workers with needle stick injuries and other risk groups, this concept has proven reliable over three decades.
With rabies, post-exposure prophylaxis has worked even longer. Louis Pasteur developed the basic principle in 1885. Proper wound care, rabies immunoglobulin, and a vaccine series are nearly 100 percent effective when applied consistently after animal contact. In both cases, the PEP strategy has demonstrated that a short window after exposure is sufficient to prevent infection if the right tool is available. For SARS-CoV-2, this tool did not previously exist. XOCOVA closes this gap.
Three questions determine how far XOCOVA will reach
FDA approval is the first step, but three conditions will determine how many people actually benefit from XOCOVA. First, price. Shionogi has not yet published a US list price. Antiviral COVID medications like Paxlovid cost several hundred US dollars per course at market launch. Whether insurance will cover costs is decisive for access.
Second, international approval. FDA approval applies exclusively to the United States. Europe, Japan (where ensitrelvir is already approved as a treatment), and other regions have separate procedures with their respective authorities. Global deployment, especially in countries with many immunocompromised patients, requires additional approvals.
Third, variants. The SCORPIO-PEP trial ran from June 2023 to September 2024. Since then, the variant spectrum of SARS-CoV-2 has evolved. Ensitrelvir targets the 3CL protease, which is evolutionarily more conserved than the spike protein, suggesting efficacy against newer variants may be maintained. However, clinical data for current variants are still pending.